Talk Global Insights track
S0404 - Japan Townhall
Tue, Mar 18, 2025 · 3:10–4:20 PM CET Shanghai 1-2 Room, Congress Center Basel
About this session
In Japan, industry, regulatory authorities, and academia are working together to improve patient access to innovative new drugs. In line with this, PMDA has initiated a new 5-year plan to promote access since April 2024. This session will focus on the attractiveness of developing and obtaining marketing approval for pharmaceutical products in Japan from both regulatory and industry perspectives.
1. Introduction to the Pharmaceuticals and Medical Devices Agency’s (PMDA’s) Plan and the Direction to Achieve It
2. Clarifying Misconceptions and Urban Legends About the Drug Development Environment, and Providing an Update on the Latest Situation in Japan
3. The Attractiveness of Performing Drug Development in Japan, from Both Regulatory and Industry Perspectives
Programme:
- 3 Japan's Attractiveness for Drug Development — Shinichi Noda
- 4. Panel Discussion — Meni Melek
- 2 Japan’s attractiveness for drug development — Eri Sekine
- 1. Setting the scene — Daisuke Tanaka
Speakers
-
Office Director, Office of International Programs · Pharmaceuticals and Medical Devices Agency (PMDA)
Chair
